Ceva announces important advances inthe control of respiratory disease in poultry

Ceva Vaccination Summit details new claims for IB Vaccines.
calendar icon 19 May 2017
clock icon 3 minute read

Consumer demand is having significant impact on the way that poultry is produced. Up to 40% of broilers are now reared for 8-9 weeks, as producers respond to evolving consumer demand for more taste from ethically reared birds or new cooked lifestyle products.

Ceva was recently granted new claims in Europe to use Cevac Ibird® & Cevac Mass L in combination, the first programme of its kind, which offers 9 weeks duration of immunity.

Combined vaccination will also simplify programmes for layer pullets with less revaccination required during rearing. Safe repeated use during laying period claim of Cevac IBird® is matching to practice to vaccinate layers in lay, in order to lower drop in egg production & improve eggshell quality.

A further benefit is that this new generation of vaccines reduces the virus load in the trachea. A unique claim that underpins Ceva’s central Vaccinology message, Dr. Pascal Paulet, Head of Poultry marketing commented:

“Achieving simple disease protection through vaccination is no longer enough, the new standard means that today’s vaccines must also be capable of reducing overall disease pressure by minimising circulation of field viruses.”

About Ceva Santé Animale
Ceva Santé Animale is a French multinational veterinary pharmaceutical company created in 1999. Chaired by Dr Marc Prikazsky, Ceva specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals. Ceva is present in 110 countries and employs almost 4,500 people worldwide.

Website: www.ceva.com

© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.